Bedford Laboratories(TM) to Begin Shipping Ondansetron Injection USP.

All rights reserved.. Thisproduct is AP rated and is equivalent to Zofran(R) by GlaxoSmithKline.Ondansetron Injection USP is indicated for prevention of nausea andvomiting associated with initial and repeat courses of emetogenic cancerchemotherapy, including high-dose cisplatin. 26 /PRNewswire/ -- Bedford Laboratories(TM), adivision of Ben Venue Laboratories Inc., announced that it will beginmarketing Ondansetron Injection USP as of December 26, 2006. Headquartered in Bedford,
Ohio, Bedford Laboratories is a division of Ben Venue Laboratories,
Inc., a subsidiary of Boehringer Ingelheim Corporation located in
Ridgefield, CT, and is a part of the Boehringer Ingelheim group of
companies.

The Boehringer Ingelheim group is one of the world's 20
leading pharmaceutical companies. Since it was founded in 1885, the
family-owned company has been committed to researching, developing,
manufacturing and marketing novel products of high therapeutic value for
human and veterinary medicine.

In 2005, Boehringer Ingelheim posted net sales of US $11.8 billion
(9.5 billion euro) while spending approximately one-fifth of net sales
in its largest business segment, Prescription Medicines, on research and
development.

For more information http://zofranrecallcenter.com/glaxosmithkline-gsk-zofran-manufacturer-company-detail-and-history/ - Zofran settlement - please visit
http://www.boehringer-ingelheim.com/

CONTACT: Jason Kurtz of Bedford Laboratories, 1-800-562-4797, ext
3668

Web site: http://www.bedfordlabs.com/
http://www.boehringer-ingelheim.com/

COPYRIGHT 2006 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. BEDFORD, Ohio, Dec. Headquartered in Ingelheim, Germany,
it operates globally with 143 affiliates in 47 countries and
approximately 37,500 employees. It is also indicated forprevention of postoperative nausea and/or vomiting."As part of our objective to offer an extensive selection of
specialty products to meet the changing needs of healthcare
professionals, we are pleased to announce the addition of Ondansetron
Injection USP to our portfolio," said David Gaugh, General Manager
of Bedford Laboratories.

Bedford Laboratories will supply Ondansetron Injection USP, 2mg/mL
packaged in 4mg/2mL single-dose vials and 40mg/20mL http://www.drugs.com/zofran.html - http://www.drugs.com/zofran.html - multi-dose vials.
Prescribing information is available upon request from the Bedford
Laboratories' professional services department, (800) 521-5169, or
from the company's web site, http://www.bedfordlabs.com/.

Bedford Laboratories supplies the US and International markets with
multisource and specialty injectable products